The stock of Cellectis SA (ADR) (NASDAQ:CLLS) gapped down by $0.05 today and has $22.08 target or 5.00% below today’s $23.24 share price. The 5 months technical chart setup indicates high risk for the $819.20M company. The gap down was reported on Oct, 4 by Barchart.com. If the $22.08 price target is reached, the company will be worth $40.96M less.
Gaps down are helpful for identifying a resistance level and to could also be used as a tradeable event. If traders are short the stock and it experiece gap down, then its usually advisable to hold the short for a bigger down move. Back-tests of such patterns show that two-thirds of the these patterns the stock performance worsens after the gap. The area gaps close 91% of the time, the breakaway gaps 1%, the continuation gaps 9% and the exhaustion gaps 64%. The stock decreased 3.49% or $0.84 during the last trading session, hitting $23.24. About 119,994 shares traded hands or 37.79% up from the average. Cellectis SA (ADR) (NASDAQ:CLLS) has declined 7.56% since March 1, 2016 and is downtrending. It has underperformed by 19.77% the S&P500.
According to Zacks Investment Research, “Cellectis SA is a gene-editing company. The company focused on developing immunotherapies based on gene edited engineered CAR-T cells. Cellectis SA is based in Paris, France.”
More notable recent Cellectis SA (ADR) (NASDAQ:CLLS) news were published by: Quotes.Wsj.com which released: “DOW JONES, A NEWS CORP COMPANY” on March 21, 2015, also Marketwatch.com with their article: “Virtual Stock Exchange” published on March 25, 2015, Schaeffersresearch.com published: “Cellectis SA (CLLS) Defies Sector Headwinds on Cancer Breakthrough” on May 06, 2016. More interesting news about Cellectis SA (ADR) (NASDAQ:CLLS) were released by: Bidnessetc.com and their article: “Pfizer Inc. Interested In Acquiring French Biotech Firm Cellectis SA (ADR …” published on June 01, 2015 as well as Benzinga.com‘s news article titled: “BofA Starts Cellectis At Buy, Sees Plant Sciences As ‘Hidden Gem'” with publication date: July 20, 2015.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.